Introduction
Bone aging, the main risk factor for primary osteoporosis, results in a decrease in bone mass and a parallel increase of BM adiposity (1) (2) (3) . At the cellular level, BM mesenchymal stem/progenitor cells (MSCs), which are the common progenitors from which osteoblasts and adipocytes arise, undergo senescence along with bone aging (4) . Anatomically, MSCs, defined as PDGF-α + Sca1 +
CD31
-CD45 -, reside primarily within the perivasculature -a region that can be specifically targeted by nestin-Cre (5), Prx1-Cre (6), or Lepr-Cre (7) . As compared with young cells, senescent MSCs have reduced self-renewal capacity and predominantly differentiate into adipocytes as opposed to osteoblasts (8, 9) . Such osteogenic or adipogenic commitment of MSCs is controlled by several crucial transcription factors. For example, PPARγ and CEBPα/β/δ constitute an essential cascade for the adipocyte program, whereas RUNX2 and osterix are master regulators of osteoblast differentiation (10) (11) (12) .
Cellular senescence, a state of irreversible growth arrest, is mainly controlled by the p16 INK4A /Rb and p19 ARF /p53 pathways (13, 14) . p16
INK4A is required for the age-associated decline in function of a number of adult stem cells (15) (16) (17) (18) , including BM MSCs (19) . p53-Deficient mice display osteoporosis and other aging-related features (20) . Alterations in the transcriptional control or activity of these pathways account for the aging-related features detected in mice deficient for Bmi-1 (21) , Brac1 (22) , Zmpste24 (23) , Hmga2 (24) , or BUBR1 (25) . In addition, Rb determines cell-fate choice and prevents premature aging of MSCs (26, 27) . However, the molecular network orchestrating adipo-osteogenic balance and cellular senescence of MSCs remains largely unknown.
Forkhead box P1 (FOXP1) is a transcriptional factor that controls multiple cell-differentiation pathways, including embryonic stem cell pluripotency (28) , T and B cell development (29) (30) (31) , lung epithelial cell-fate determination (32) (33) (34) (35) , cardiomyocyte proliferation (33, 36) , hair follicle stem cell quiescence (37) , neuronal activity (38, 39) , and glucose homeostasis (40) . FOXP1 haploinsufficiency in humans leads to deformity in craniofacial structure and speech ability (41) . In this study, we observed that Foxp1 deficiency in MSCs resulted in prototypical premature bone aging. These and additional results herein suggest that age-dependent bone loss may, in part, be orchestrated by the multifaceted action of FOXP1 during differentiation and senescence of MSCs.
Results

Foxp1 expression in BM MSCs declines with age.
Nestin + MSCs in BM represent a population that constitutes an essential hematopoietic stem cell (HSC) niche (5) . Immunohistochemical (IHC) examination revealed colocalization of nestin and FOXP1 in a subset of stromal cells within neonatal BM in vivo ( Figure 1A ). Colocalization was validated in vitro in a subpopulation of MSC in cultures (Supplemental Figure 1A ; supplemental material available online with this article; https://doi.org/10.1172/JCI89511DS1). Of the 4 alternatively spliced FOXP1 isoforms in mouse tissues (42), we detected 3 in BM MSCs: FOXP1A, FOXP1D, and FOX-A hallmark of aged mesenchymal stem/progenitor cells (MSCs) in bone marrow is the pivot of differentiation potency from osteoblast to adipocyte coupled with a decrease in self-renewal capacity. However, how these cellular events are orchestrated in the aging progress is not fully understood. In this study, we have used molecular and genetic approaches to investigate the role of forkhead box P1 (FOXP1) in transcriptional control of MSC senescence. In bone marrow MSCs, FOXP1 expression levels declined with age in an inverse manner with those of the senescence marker p16
INK4A
. Conditional depletion of Foxp1 in bone marrow MSCs led to premature aging characteristics, including increased bone marrow adiposity, decreased bone mass, and impaired MSC selfrenewal capacity in mice. At the molecular level, FOXP1 regulated cell-fate choice of MSCs through interactions with the CEBPβ/δ complex and recombination signal binding protein for immunoglobulin κ J region (RBPjκ), key modulators of adipogenesis and osteogenesis, respectively. Loss of p16 INK4A in Foxp1-deficient MSCs partially rescued the defects in replication capacity and bone mass accrual. Promoter occupancy analyses revealed that FOXP1 directly represses transcription of p16
. These results indicate that FOXP1 attenuates MSC senescence by orchestrating their cell-fate switch while maintaining their replicative capacity in a dose-and age-dependent manner. ( Figure 1F ). This inverse correlation was recapitulated in cultures of MSCs expanded in vitro for 6 passages (P1 to P6; Figure 1G ). Figure 1B and Supplemental Figure 1B ). Foxp1 expression declined progressively in mice during their progression from adolescence (1 month) to aged (8 to 30 months; Figure 1B 
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-(Supplemental Figure 1, C and D) . The expression decline was observed INK4A expression levels during in vitro expansion and passaging (P1-P6) of murine MSCs. n = 3. (H) Methylation of CpG islands within the Foxp1 promoter variant 3 (-196 to 1) as detected by bisulfite sequencing in 1-and 12-month-old MSCs. Black circles represent methylated CpG islands and white circles unmethylated CpG islands. n = 3. *P < 0.05; **P < 0.01. Next, we stably overexpressed Foxp1 in C3H10T1/2 mesenchymal cells by retroviral transduction. We then assessed cell differentiation either by oil red O staining 6 days after adipogenic induction or by alkaline phosphatase (ALP) staining 14 days after Figure 4N ). These findings suggest that FOXP1 promotes osteogenic differentiation of MSCs through repression of Notch signaling during postnatal skeletal aging. However, further studies are needed to more robustly confirm this hypothesis.
Foxp1 attenuates MSC senescence through repression of p16 INK4A transcription. In terms of stem cell replication capacity, explants of Foxp1 Prx1 Δ/Δ MSCs displayed marked arrest in population doubling measured in vitro at 1 and 6 months ( Figure 5A ). Following 48-hour BrdU pulse-chase, FACS analyses revealed a smaller proportion of BrdU
Δ/Δ mice ( Figure 5 , B and C). We further observed that expression levels of cell cycle inhibitors p16
INK4A
, p21, and p27 were relatively increased in MSCs following isolation from Foxp1-deficient BM ( Figure 5D ). However, the number of CFU-F colonies began to progressively decrease at 6 months ( Figure 5 , E and F), consistent with a reduction in self-renewal ability upon loss of Foxp1. Expression levels of p16 INK4A , a marker for cellular senescence (18) , were also significantly increased ( Figure 5G ). Yet expression of another 2 aging-associated markers, H3K9me3 and LAP2β (50), was decreased in Figure 8D ). This decreased distribution of nuclear LAP2β in Foxp1-deficient MSCs was confirmed by high-resolution IHC ( Figure 5H ) and was consistent with the Western blot data ( Figure 5G ). These in vivo and in vitro experiments indicated that Foxp1-deficient MSCs undergo a decline in self-renewal capacity. This, in turn, leads to swift accumulation of DNA damage and premature senescence during expansion.
Tight transcriptional control of the p16 INK4A locus is important in regulating senescence of a number of adult stem cell lineages during aging (13, 14, 51, 52) . Promoter occupancy analysis identified FOXP1-binding sites within the p16 INK4A promoter (-1701 to-1695, Figure 6A ). Luciferase reporter assays employing p16-Luc (driven by its essential 2.8 kb promoter) revealed that FOXP1 repressed activity of the p16 INK4A WT, but not the FOXP1-binding site-mutated p16
INK4A reporter ( Figure 6 , B and C). These findings suggested that FOXP1 restrains MSC senescence through repression of p16 INK4A transcription during skeletal aging.
To further test this hypothesis, we investigated the phenotypes of doubly deleted Foxp1 and p16 INK4A conditional KO mice (Foxp1 Prx1
). Even though singular loss of p16 INK4A had shown no effect on MSC expansion or bone growth at 3 months of age as described previously (52), we observed a partial rescue of the replicative capacity in Foxp1 Prx1 Δ/Δ p16 -/-double-mutant mice ( Figure 6D ). μCT analyses of bone parameters showed that, as compared with single Figure 3G ). Collectively, our observations suggest that a FOXP1-CEBPβ/δ complex attenuates Pparg transcription to restrain adipogenic differentiation of MSCs.
Notch/recombination signal binding protein for immunoglobulin κ J region (RBPjκ) signaling maintains MSC identity by suppressing osteoblast differentiation (48, 49) . Via co-IP, we detected interaction of FOXP1 with RBPjκ in both C3H10T1/2 mesenchymal cells and BM MSCs (Figure 4 , J and K). Colocalization of FOXP1 and RBPjκ protein within C3H10T1/2 nuclei was also detected ( Figure 4D and Supplemental Figure 8B ). Next, we observed that, through this interaction, FOXP1 repressed the acti- Overexpression of FOXP1 in human mesenchymal progenitors augments their replication capacity. Given that Foxp1 expression correlated with the aging progress of murine MSCs, we tested whether overexpression of FOXP1 could compromise senescence in human mesenchymal progenitor cells (hMPCs). Overexpression of lentiviral FOXP1 (Supplemental Figure 8E ) within hMPCs collected from donors of both sexes at ages ranging from 27 to 82 years significantly augmented their replicative capacity, as assessed by measurement of population doubling (Figure 7, A-D) . Of note, overexpression of FOXP1 hMPCs from a 74-year-old donor increased their expansion capacity to levels comparable to that of hMPCs from a 27-year-old donor (Figure 7D) . This was coupled with a dramatic repression of p16
transcription within the fifth passage of FOXP1-overexpressing hMPCs ( Figure 7E ). We also observed that hMPCs transduced with Foxp1 had greater osteogenic potential and reduced adipogenic potential, as evidenced by ALP and oil red O staining, by qPCR for osteogenic markers (ALP, COL1A1, HEY1 and HEYL), and by Western blotting for adipogenic markers (PPARγ and FABP4) (Figure 7 , F-H). Collectively, our results indicate that FOXP1 is capable of augmenting the replication capacity of hMPCs irrespective of their age.
Discussion
Studies of mesenchymal progenitor-associated transcription factors in humans first reported that FOXP1 expression was higher in hMPCs than in their differentiated progenies (53) . Expanding upon that observation, we identified FOXP1 as a dose-dependent orchestrator of MSC senescence and differentiation potency during skeletal aging. Our data suggest a model in which high levels of FOXP1 expression in young MSCs prevent their premature senescence, leading to an outcome that favors bone formation over adipogenesis ( Figure 7I ). In aged MSCs, a decline in FOXP1 levels alleviates negative regulation of p16 INK4A transcription and adipogenesis to promote the aging of MSCs ( Figure 7I) .
In a previous study, neither FOXP1 nor p16 INK4A expression was found to significantly decrease in MSCs from middle-aged to elderly donors (54) . Perhaps FOXP1 expression in MSCs from middle-aged donors had already begun to decrease when their measurements were made. In support of this interpretation, Foxp1 expression in 8-month-old murine MSCs decreased approximately 60% as compared with that in 1-month-old mice (Figure 1, B and F) .
Epigenetic modifications, such as promotor-associated DNA methylation, appear to be a hallmark of MSC senescence (55) . DNA methylation within the Foxp1 promoter region is increased with age, thereby potentially contributing to the progressive downregulation of Foxp1 expression. That FOXP1 directly represses Pparg transcription in MSCs may, at least in part, explain the chronic increase of PPARγ expression in senescent MSCs (56) . PPARγ acts as a master regulator of adipocyte differentiation by suppressing osteoblast differentiation (57) (58) (59) . Thus, we contend that a decrease in FOXP1 levels, coupled with augmentation of PPARγ expression, contributes to the increased adiposity in aged bones. We also found that FOXP1 may restrain the osteogenic potential of MSCs by suppressing Notch signaling ( Figure 4, J-N) . Collectively, our data indicate that FOXP1 acts as a critical effector of aging by controlling adipo-osteogenic balance during MSC differentiation.
A previous study claimed that siRNA-mediated knockdown (KD) of FOXP1 impaired adipogenesis, but not osteogenic differentiation, when tested in vitro (53) . However, the efficacy and specificity of FOXP1 KD -a critical parameter for drawing this conclusion -were not presented in this study. Given the highly conserved sequence and redundant functions of FOXP1/2/4 isoforms (60), one cannot exclude the possibility that inefficient and/ or mistargeted KD led to this conclusion.
Our results, derived both from in vivo and in vitro analyses, demonstrated a critical function for FOXP1 in fate choice of MSC differentiation. In addition, elevation of FOXP1 expression in aged hMPCs reversed their decline in expansion capacity and osteogenic potential. The current anabolic targets for osteoporosis, such as parathyroid hormone (PTH) or Wnt agonists, mainly promote osteoblastogenesis in bone formation (61) . The multiple actions of FOXP1 in regulating MSC plasticity and senescence engender it as a potential anabolic target for osteoporosis therapy.
A central finding of our study is that FOXP1 attenuates MSC aging by directly regulating p16 INK4A transcription. Most relevant to this, FOXP1 overexpression has been associated with a variety of cancers (62) (63) (64) (65) (66) (67) (68) (69) (70) (71) . Given that the state of senescence can protect cells against the development of cancer (14), we submit that our findings may be instructive in understanding FOXP1-associated mechanisms of multiple tumorigenesis. Further studies are needed to address how the FOXP1/p16 cascade protects multiple cell lineages against premature senescence or unlimited overgrowth.
Methods
Mice. Foxp1
fl/fl (29) , p16 -/- (17) , Prx1-Cre (72) , and nestin-Cre (5) mice were generated as described elsewhere. The genetic backgrounds of all KO mice were uniform mixtures of 129S1/SvIMJ and C57BL/6. Mice were bred in pathogen-free conditions. -FOXP1 (N) . n = 3. *P < 0.05; **P < 0.01; ***P < 0.001.
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jci.org Volume 127 Number 4 April 2017 Δ/Δ BM at 3 months old. n = 4. *P < 0.05; **P < 0.01; ***P < 0.001. CTAn software. The region of interest (ROI) selected was 5 mm below the growth plate of bones. Cell cultures. Mouse MSCs were enumerated and expanded using the mouse MesenCult Proliferation Kit (STEMCELL Technologies) according to the manufacturer's protocols. Briefly, mouse BM cells from tibia and femur were flushed out with 2 ml IMDM with 2% FBS and filtered through a 70-μm cell strainer (BD Falcon). Nucleated cells were counted using acetic acid with methylene blue. Cell numbers and volumes were adjusted using MesenCult medium (STEMCELL Technologies) according to assay requirements. Cell lines C3H10T1/2 and 3T3-L1 were obtained from ATCC.
qPCR. Total RNA was extracted with TRIzol reagent (Invitrogen), and cDNA was generated using the GoScript Reverse Transcription System (Promega). Real-time qPCR was performed with the ABI 7500 System (Applied Biosciences) using SYBR Green (Roche). The primers used for qPCR are listed in Supplemental Table 1 .
Osmium tetraoxide staining and μCT analysis. Femurs or tibias were dissected from mice and fixed in 70% ethanol at 4°C. To visualize and quantify BM fat, bones were decalcified and stained by osmium tetraoxide as described previously (73) . μCT scanning of bone and fat was performed on SkyScan 1176 (Bruker). A 3D model was reconstructed, and structural indices were calculated using For mouse CFU-F assays, 2 million BM cells were plated per well in 6-well plates, each group was plated in duplicate or triplicate, and cells were cultured for 14 days at 37°C in 5% CO 2 . CFU-F-derived colonies were stained by Giemsa staining solution and enumerated. INK4A to maintain the replication capacity of MSCs while sustaining osteogenic rather than adipogenic differentiation. In old MSCs, reduction of Foxp1 expression releases p16 INK4A repression, leading to impaired MSC replication capacity while promoting adipogenic differentiation at the expense of osteogenic differentiation. *P < 0.05; **P < 0.01; ***P < 0.001. Immunohistochemistry and confocal microscope. Cultured MPCs were fixed in 4% PFA for 10 minutes at room temperature. After blocking with 10% normal goat serum, cells were then incubated with γH2A antibody (GeneTex, GTX11174, 1:500), Ki67 antibody (Abcam, ab15580, 1:500), and LAP2β (BD, 611000, 1:500), followed by incubation with Alexa Fluor 488-or Alexa Fluor 594-conjugated secondary antibodies. For SA-β-gal staining, cells were fixed with 0.5% glutaraldehyde in PBS (pH 7.2) for 5 minutes at room temperature, then washed with PBS containing MgCl 2 (pH 7.2, 1 mM MgCl 2 ) and stained with X-gal solution (1 mg/ml X-gal, 0.12 mM K 3 Fe[CN] 6 , 1 mM MgCl 2 in PBS, pH 6.0) overnight at 37°C.
Bones were fixed in 4% PFA for 24 hours at 4°C, decalcified in 10% EDTA (pH 7.4) for 21 days, embedded in paraffin or tissue-freezing medium (Leica), and sectioned to 8 μm. For immunofluorescence, heat-induced antigen retrieval with sodium citrate buffer (10 mM sodium citrate, 0.05% Tween 20, pH 6.0) was performed before bone sections were blocked with 10% normal serum containing 1% BSA in TBST (pH 7.6) for 2 hours at room temperature, then incubated overnight at 4°C with primary antibodies to mouse FOXP1 (Millipore, ABE68, 1:100) and Nestin (Abcam, ab11306, 1:100) diluted in TBST with 1% BSA. Subsequently, sections were incubated with secondary fluorescentconjugated antibodies at room temperature for 2 hours in the dark. Samples were imaged by the Leica TCS SP5 confocal microscope, the Leica DM2500, or the 3000B microscope. H&E staining was conducted according to standard protocols.
Flow cytometry analysis. For BrdU labeling of MSCs, mice were intraperitoneally injected with BrdU (100 μg/g of body mass, SigmaAldrich) and sacrificed 48 hours later. BM cells were flushed out and collected in DMEM with 2% FBS, then diluted to 8 million cells in 400 μl of medium and incubated with anti-mouse CD45-APC (17-0451, eBioscience), CD11b-APC (17-0112, eBioscience), Ter119-APC (17-5921, eBioscience), CD31-APC (17-0311, eBioscience), Sca1-PerCP (45-5981, confluence. Cells were cultured for 1 week before oil red O staining. Oil red O staining was performed according to standard protocols. For population doubling assays, the first passaged mouse MSCs were seeded in 10-cm plates with 5 × 10 6 cells and hMPCs were seeded in 35-mm dishes with 1 × 10 5 cells. Medium changes were performed every 3 days and cells passaged at weekly intervals. Cells were counted at each passage to calculate population doublings. hMPCs were isolated from vertebrae or femur bones of trauma patients between 20 and 80 years old. hMPCs were then separated using the Human Marrow Lymphocyte Medium Kit (Sangon Biotech) and cultured using the MesenCult Proliferation Kit (human) (STEM-CELL Technologies). For osteogenic differentiation of human mesenchymal stem cells, 0.1 million hMPCs were seeded per well of 24-well plates with the same medium for CFU-Ob assays above. After 9 days of induction, cells were fixed and stained for ALP.
Viral infection. To obtain transformants stably expressing FOXP1, pMSCV-FOXP1-puro and pMSCV-GFP-puro control retroviruses were transfected into Plat-E packaging cells using FuGENE HD (Promega). After 48 hours, culture supernatants were collected and used for infection. Retroviruses were introduced into C3H10T1/2 cells, and stable transformants were selected with 5 μg/ml puromycin. For osteoblast and adipocyte differentiation, cells were cultured in osteogenic medium and adipogenic medium described above, respectively. For lentivirus infections, hMPCs were plated at a density of 1 × 10 5 cells in 3.5-mm dishes.
LV-FOXP1 or LV-GFP virus was added at a multiplicity of infection of 20, and cells were exposed to virus for 24 hours and selected with 1 μg/ml puromycin for 3 days. Lentiviruses were obtained from Hanbio. ChIP assay. Briefly, after MSCs were isolated from mouse BM and cultured for 2 weeks, chromatin was crosslinked with 1% formaldehyde and sheared to 300-to 500-bp fragments by sonication (Sonics VCX130, 30% amplitude, 5 seconds on and 10 seconds off for 16 cycles). FOXP1 antibody (Millipore, ABE68, 1:200) and normal rabbit IgG (Santa Cruz Biotechnology Inc., sc-2027, 1:80) were used to immuno precipitate the relevant protein-DNA complex. The crosslinked DNA and protein were reversed by addition of 5 M NaCl; DNA was extracted by phenol/chloroform and precipitated with ethanol and glycogen. Purified DNA was quantified using real-time PCR. The primer sequences are listed in Supplemental Table 1 .
Luciferase reporter assay. Luciferase assays were performed in HEK293T, C3H10T1/2, or 3T3-L1 cells. The reporter plasmid PpargLuc, containing a 2.2-kb fragment of the 5′ flanking region of the Pparg gene, was obtained from Hiroshi Takayanagi (Tokyo Medical and Dental University, Tokyo, Japan). The RBP-JK luciferase reporter plasmid and expression plasmid with NICD2 were provided by Lianping Xing (University of Rochester Medical Center, Rochester, New York, USA). The p16
INK4A
-luc reporter plasmid, which contains a 2.8-kb fragment of the 5′ flanking region of the p16 INK4A gene, was constructed in our lab.
The mutant p16
-luc reporter plasmid was generated by replacing the putative FOXP1-binding site (TATTTAT) at position -1701 with the random sequence GCGGGCG. The expression plasmids of FOXP1, CEBPα, CEBPβ, and CEBPδ were constructed into the pcDNA3.0 vector. Cells were transfected using Lipofectamine 2000 (Invitrogen) in 24-well plates. The transfection amount of each plasmid was 200 μg, and the total amount of transfected DNA was kept consistent across each transfection condition of pcDNA3.0 empty plasmids where necessary. After 32 hours, dual luciferase assay was performed according to the manufacturer's protocols (Promega).
